Cardiovascular disease (CVD) is the leading cause of mortality in people with type 2
diabetes mellitus (T2DM), yet a significant proportion of the disease burden cannot be …

Glucagon-like peptide-1, produced predominantly in enteroendocrine cells, controls glucose
metabolism and energy homeostasis through regulation of islet hormone secretion …

Objective Epicardial adipose tissue (EAT), the visceral fat depot of the heart, is a modifiable
cardiovascular risk factor and emerging therapeutic target. Liraglutide, an analog of …

Diabetic patients are frequently affected by coronary microvascular dysfunction (CMD), a
condition consisting of a combination of altered vasomotion and long-term structural change …

The treatment landscape for patients with established or at high risk for cardiovascular
disease and type 2 diabetes mellitus has entirely changed over the past decade, with the …

Aim The cardiovascular benefits provided by glucagon‐like peptide‐1 receptor agonists
(GLP‐1RAs) extend beyond weight reduction and glycaemic control. One possible …

Background Incretin-based agents, including dipeptidyl peptidase-4 inhibitors (DPP-4Is) and
glucagon-like peptide-1 agonists (GLP-1As), work via GLP-1 receptor for hyperglycemic …

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used to treat patients
with type 2 diabetes since 2005 and have become popular because of the efficacy and …

Background Macrophages play a pivotal role in atherosclerotic plaque development. Recent
evidence has suggested the glucagon-like peptide-1 receptor (GLP-1R) agonist, liraglutide …

Aim To conduct a meta‐analysis of cardiovascular outcome trials on the effects of glucagon‐
like peptide‐1 receptor agonists (GLP‐1RAs) on major adverse cardiovascular events …